SCHUCHERT JOSEPH S

Form 4

December 22, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

SECURITIES

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * KELSO PARTNERS V L P

2. Issuer Name and Ticker or Trading

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last)

(First)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

Director Officer (give title

below)

_X__ 10% Owner _ Other (specify

12/13/2005

(Street)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Person

NEW YORK, NY 10022

320 PARK AVENUE

(City)	(State)	Zip) Table	I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securitin(A) or Dis (Instr. 3, 4)	posed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
Common Stock, par value \$.01 per share (1)	12/13/2005		X	7,975	D	\$ 2.42	15,704,006	I	by Endo Pharma LLC (2) (3)
Common Stock, par value \$.01 per share (1)	12/13/2005		X	2,311	D	\$ 2.42	15,701,695	I	by Endo Pharma LLC (2) (3)
Common Stock, par value \$.01 per share (1)	12/13/2005		X	1,216	D	\$ 2.42	15,700,479	I	by Endo Pharma LLC (2) (3)

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

Common Stock, par value \$.01 per share (1)	12/13/2005	X	14,124	D	\$3	15,686,355	I	by Endo Pharma LLC (2) (3)
Common Stock, par value \$.01 per share (1)	12/13/2005	X	2,551	D	\$ 3	15,683,803	I	by Endo Pharma LLC (2) (3)
Common Stock, par value \$.01 per share (1)	12/13/2005	X	1,046	D	\$ 3.42	15,682,758	I	by Endo Pharma LLC (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Call Obligation (obligation to sell)	\$ 2.42	12/13/2005		X		7,975	10/13/2005	08/26/2007	Common Stock	7,975
Call Obligation (obligation to sell)	\$ 2.42	12/13/2005		X		2,311	10/13/2005	08/26/2007	Common Stock	2,311
Call Obligation (obligation to sell)	\$ 2.42	12/13/2005		X		1,216	10/13/2005	08/26/2007	Common Stock	1,216
Call Obligation (obligation	\$ 3	12/13/2005		X		14,124	10/13/2005	08/26/2007	Common Stock	14,124

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

to sell)								
Call Obligation (obligation to sell)	\$ 3	12/13/2005	х	2,551	10/13/2005	08/26/2007	Common Stock	2,551
Call Obligation (obligation	\$ 3.42	12/13/2005	X	1,046	10/13/2005	08/26/2007	Common Stock	1,046

Reporting Owners

to sell)

Reporting Owner Name / Address	Relationships						
reporting owner runner, runners	Director	10% Owner	Officer	Other			
KELSO PARTNERS V L P 320 PARK AVENUE NEW YORK, NY 10022		X					
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
Loverro Frank J C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X					
WALL THOMAS R IV C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X					
Connors James J II C/O KELSO & COMPANY 320 PARK AVENUE		X					

Reporting Owners 3

NEW YORK, NY 10022

Signatures

12/22/2005
Date
11/08/2005
Date
11/09/2005
Date
11/08/2005
Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Kelso Partners V, L.P. (KP V") is the designated filer.
- (2) KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to secutieties owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.
- Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by (3) virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuriary interest.

Signatures 4

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.